Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01587729
Other study ID # 115734
Secondary ID WEUKBRE5556
Status Completed
Phase N/A
First received April 23, 2012
Last updated March 26, 2015
Start date November 2011
Est. completion date July 2014

Study information

Verified date March 2015
Source GlaxoSmithKline
Contact n/a
Is FDA regulated No
Health authority United States: No Health Authority
Study type Observational

Clinical Trial Summary

The studies described in this protocol are all performed within the framework of PROTECT (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium) Workpackage 2 and Workgroup 1. Primary aim of these studies is to develop, test and disseminate methodological standards for the design, conduct and analysis of Pharmacoepidemiological (PE) studies applicable to different safety issues and using different data sources. To achieve this, results from PE studies on five key adverse events (AEs) performed in different databases will be evaluated. Therefore, emphasis will be on the methodological aspects of the studies in this protocol and not on the clinical consequences of the association under investigation.

Fracture of the proximal end of the femur or hip is associated with considerable morbidity and mortality. Hip/femur fractures impair quality of life and impose a considerable economic burden, and occur with 20% mortality rate within the first year. Antidepressants (AD), mainly tricyclic AD (TCAs) and selective serotonin re-uptake inhibitors (SSRIs) have been associated with fractures in several studies. A review of 13 observational studies showed risk ratios ranging from 1.2 to 3.7 for current TCA users and a wide range of 1.5 to 8.6 for SSRI users. The majority of the studies in the aforementioned review reported increased risks of fractures in general with SSRIs use and more mixed risk outcomes for TCA use. Several mechanisms underlying this adverse effect have been postulated in the literature: e.g. through decrease in bone mineral density (BMD) or through blocking the serotonin transporter activity (5-hydroxytryptamine re-uptake) and hence affecting bone metabolism and structure or simply by falling or through co-morbidities such as depression itself. Previous observational studies differ in design, conduct and analysis of the considered association with varying degree of accounting for confounders. Confounding factors such as depression and other co-morbidities, previous fractures, concomitant drug use and lifestyle factors such as smoking have usually not been accounted for in most of the studies. In addition, small sample size, different methods used to ascertain exposure, selection bias and lack of data on compliance as well as important covariates limit the use of these results in benefit-risk analyses. Furthermore, studies evaluating different types of SSRI and TCA are few and dose-response relationship for most of the AD remains to be studied. We will study effects of cumulative exposure focusing on acute (less than 6 months) and long term exposure (at least 5 years) and doses of exposure.

The objective of the study is to assess the association between AD use and hip/femur fracture using different study designs (descriptive, cohort, nested case-control and case crossover) across different databases and to compare the results between and across databases and designs. This is to evaluate the impact of design/database /population difference in the outcome of the studies association.

Data will be collected from the following databases: The Health Improvement Network [(THIN]), a UK-based primary care electronic medical record database, the Dutch Mondriaan project (a primarily general physician based database with some linkage to survey data from the Netherlands), Base de Datos para la Investigación Farmacoepidemiológica en Atencion Primaria [(BIFAP] (Spanish primary care database)), and the Bavarian statutory health insurance physicians' association database (German health insurance database from primary and secondary care).


Recruitment information / eligibility

Status Completed
Enrollment 1
Est. completion date July 2014
Est. primary completion date July 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility For the descriptive study:

Inclusion Criteria:

- patients who have at least one year of enrolment with the GP

- patients who are at least 18 years of age

- patients who have at least one antidepressant prescription

Exclusion Criteria:

- patients with an antidepressant prescription within 6 months prior to study start

- patients missing information on sex and age

Study Design

Time Perspective: Retrospective


Related Conditions & MeSH terms


Intervention

Drug:
Tricyclic AD (TCAs) and selective serotonin re-uptake inhibitors (SSRIs) antidepressants
TCA or SSRI prescription during the study period between January 1, 2001 and December 31, 2009. The TCAs and SSRIs administered to the patients include paroxetine and escitaloprim.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
GlaxoSmithKline

Outcome

Type Measure Description Time frame Safety issue
Primary First fracture of hip or femur during the study period Fracture will be defined using International Classification of Diseases version 10 (ICD-10) codes in the Bavarian database, READ codes in THIN and International Classification of Primary Care (ICPC-2) in BIFAP and Mondrian Up to nine years following drug exposure Yes
See also
  Status Clinical Trial Phase
Completed NCT04012580 - Examining the Effectiveness of Transdiagnostic, Internet-Delivered Cognitive Behaviour Therapy in New Mothers Experiencing Anxiety and Depression N/A
Recruiting NCT05813782 - The Effect of Baby Massage on Postpartum Depression and Maternal Attachment N/A
Recruiting NCT05907213 - Ketamine Tolerated Dose for Postpartum Depression and Pain After Cesarean Delivery Phase 1
Completed NCT00602732 - Interpersonal Treatment Program to Prevent Depression and Post-Traumatic Stress Disorder in Low-Income Pregnant Women With Partner Abuse Phase 1
Completed NCT00053651 - Prevention of Postpartum Depression in Low-Income Women Phase 1
Completed NCT00043602 - Clinician Managed Interpersonal Psychotherapy Phase 0
Completed NCT04169334 - Look - Your Baby is Talking to You. N/A
Completed NCT03573713 - Decreasing Stunting by Reducing Maternal Depression in Uganda: A Cluster Randomized Controlled Trial (CRCT) for Improved Nutrition Outcomes N/A
Completed NCT04043533 - The Effect of an Exercise Program in Reducing the Severity of Postpartum Depression in Women N/A
Completed NCT06070168 - Determining the Effect of Telephone Counseling Service Provided to Primiparous Mothers on Postpartum Depression N/A
Recruiting NCT05050266 - Enhancing Mental and Physical Health of Women Veterans N/A
Completed NCT02505984 - Preventing Postpartum Depression With Intranasal Oxytocin Phase 2
Recruiting NCT00251342 - Outcome of Postnatal Depression Screening Using Edinburgh Postnatal Depression Scale Phase 2/Phase 3
Completed NCT02526433 - The Impact of Creative Interventions on Symptoms of Postnatal Depression (Cohort Study) N/A
Completed NCT02526407 - The Impact of Creative Interventions on Symptoms of Postnatal Depression N/A
Completed NCT03574766 - Meditation for NICU Moms N/A
Completed NCT03646539 - RCT of Automated Conversational Agent vs. Treatment as Usual for the Management of Perinatal Mood N/A
Active, not recruiting NCT05110456 - To Evaluate the Effectiveness of a Virtual and Telephone Intervention for the Prevention of Postpartum Depression in Women at Risk N/A
Recruiting NCT04154423 - Engaging Mothers & Babies; Reimagining Antenatal Care for Everyone (EMBRACE) Study N/A
Not yet recruiting NCT04093791 - MAMA NO STRESS Project. The Effects of the "HAPPY MAMA" Intervention N/A